You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 30, 2025

Claims for Patent: 6,749,864

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,749,864

Title:	Stabilized pharmaceutical composition
Abstract:	The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.
Inventor(s):	Makino; Tadashi (Osaka, JP), Tabata; Tetsuro (Osaka, JP), Hirai; Shin-Ichiro (Kyoto, JP)
Assignee:	Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:	10/335,421
Patent Claims:	1. A stabilized pharmaceutical composition for the inhibition of gastric acid secretion, comprising an effective amount of a benzimidazole compound of the formula (I) ##STR8## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy hydroxyalkyl, trifluoromethyl, acyl carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl; R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl; R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy; R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy; and m is an integer from 0 to 4, or a derivative thereof or salt thereof having a gastric acid secretion inhibitory property, and a basic inorganic salt stabilizing agent, wherein the stabilizing agent is a basic inorganic salt of at least one selected from the group consisting of magnesium, calcium, potassium, and sodium and the stabilizing agent is homogenously admixed with the compound of the formula (I) in an effective amount to provide stability to the compound of the formula (I). 2. A composition of claim 1, wherein the basic inorganic salt stabilizing agent is a basic inorganic salt of magnesium or calcium. 3. A composition of claim 1, wherein the basic inorganic salt stabilizing agent is a basic inorganic salt of sodium. 4. A composition of claim 1, wherein the basic inorganic salt stabilizing agent is a basic inorganic salt of potassium.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.